FDMT Q2 2024 Earnings — 4D Molecular Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FDMT4D Molecular Therapeutics, Inc.

$468M

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$5,000-97.9% YoY

Gross Profit

-$32M-637100.0% margin

Operating Income

-$42M-849120.0% margin

Net Income

-$35M-699060.0% margin

EPS (Diluted)

$-0.63

QoQ Revenue Growth

-82.1%

Cash Flow

Operating Cash Flow

-$30M

Free Cash Flow

-$31M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$620M

Total Liabilities

$32M

Stockholders' Equity

$588M

Cash & Equivalents

$189M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$5,000	$239,000	-97.9%
Gross Profit	-$32M	-$23M	-36.5%
Operating Income	-$42M	-$32M	-32.1%
Net Income	-$35M	-$30M	-18.0%

Revenue Segments

Collaboration And License Revenue

$5,000100%

Geographic Segments

UNITED STATES

$5,000100%